HUTCHMED (China) Limited
HealthcareNASDAQ:HCM · NASDAQ Global Select
+$0.28 today
Vol 0.03M · Avg 0.04M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
37.0%
avg -8.6%
ROIC
-3.3%
avg -20.2%
ROA
26.1%
avg -5.8%
Analysis
ROE is currently the strongest return metric at 37.0% versus its period average of -8.6%. 2 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Weiguo Su | Chief Executive Officer, Chief Scientific Officer & Executive Director (Leave of Absence) | $1.75M | — | 67 | $132,864.00 | 0.08% |
Chig Fung Cheng | Acting Chief Executive Officer, Chief Financial Officer & Executive Director | $1.16M | — | 59 | $26,307.00 | 0.02% |
Kin Hung Lee | Senior Vice President of Corporate Management & Communications | — | — | 49 | — | — |
Yiling Cui | Executive Vice President & Head of Operations | — | — | — | — | — |
Qingmei Wang | Executive Vice President of Business Development & Strategic Alliances | — | — | 63 | — | — |
Thomas Fu | Senior Vice President of Global Quality | — | — | — | — | — |
David Ng | Head of Investor Relations & Capital Strategies | — | — | — | — | — |
Xinhui Hu | Executive Vice President & Chief Technical Officer | — | — | 53 | $0.00 | <0.01% |
Charles George Rupert Nixon | Group General Counsel | — | — | 56 | $7,644.00 | <0.01% |
Selina Zhang | Senior Vice President of Global Human Resources | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
No insider transactions in the last 12 months.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | +99.7% | +13.5% (15yr)13 analysts |
| Net Income | N/A | N/A | +30.0% | +24.1% (15yr)13 analysts |
| EBIT | N/A | N/A | N/A | N/A13 analysts |
Analysis
Recent growth has been strongest in Revenue at +99.7% over three years. Forward estimates point to Net Income at +24.1% (15yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Cidara Therapeutics, Inc.
CDTX
$5.61B
Scholar Rock Holding Corporation
NASDAQ:SRRK
$5.29B
Kiniksa Pharmaceuticals, Ltd.
NASDAQ:KNSA
$3.90B
Catalyst Pharmaceuticals, Inc.
NASDAQ:CPRX
$3.84B
Adaptive Biotechnologies Corporation
NASDAQ:ADPT
$2.82B
Supernus Pharmaceuticals, Inc.
NASDAQ:SUPN
$2.58B
IDEAYA Biosciences, Inc.
NASDAQ:IDYA
$2.55B
Bausch Health Companies Inc.
NYSE:BHC
$1.89B
Mineralys Therapeutics, Inc.
NASDAQ:MLYS
$1.57B
Perrigo Company plc
NYSE:PRGO
$1.52B
Who manages HCM?
HUTCHMED (China) Limited (HCM) lists 10 active executives. The top listed executive is Kin Hung Lee, Senior Vice President of Corporate Management & Communications.
Are HCM insiders buying or selling?
Recent insider activity shows net buying of $0.00.
Explore More
Continue the stock analysis
Jump to another research area for this company.